GeoVax Labs Balance Sheet Health
Financial Health criteria checks 4/6
GeoVax Labs has a total shareholder equity of $8.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.1M and $2.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$8.59m |
| Equity | US$8.50m |
| Total liabilities | US$2.61m |
| Total assets | US$11.11m |
Recent financial health updates
Recent updates
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Sep 08
GeoVax: Possible Vaccine Advancements In 2 Big Indications
Aug 08GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine
Jul 28Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
May 24GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
Dec 27We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Nov 27GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program
Oct 03We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Aug 14Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?
Feb 18GeoVax soars on NIAID grant for COVID-19 vaccine candidate
Jan 11Financial Position Analysis
Short Term Liabilities: GOVX's short term assets ($10.9M) exceed its short term liabilities ($2.6M).
Long Term Liabilities: GOVX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: GOVX is debt free.
Reducing Debt: GOVX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GOVX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GOVX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 45.8% each year